The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

Georgina V. Long,Celeste Lebbe,Victoria Atkinson,Mario Mandalà,Paul Nathan,Ana Arance,Erika Richtig,Naoya Yamazaki,Caroline Robert,Dirk Schadendorf,Hussein Abdul-Hassan Tawbi,Paolo A. Ascierto,Antoni Ribas,Keith T. Flaherty,Neha Pakhle,Aisha Masood,Eduard Gasal,Reinhard Dummer

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

2020

Georgina V. Long
Celeste Lebbe
Victoria Atkinson
Mario Mandalà
Paul Nathan
Ana Arance
Erika Richtig
Naoya Yamazaki
Caroline Robert
Dirk Schadendorf
Hussein Abdul-Hassan Tawbi
Paolo A. Ascierto
Antoni Ribas
Keith T. Flaherty
Neha Pakhle
Aisha Masood
Eduard Gasal
Reinhard Dummer

10028Background: Treatment (tx) with checkpoint inhibitors or targeted therapy improves outcomes in patients (pts) with BRAF V600–mutant advanced melanoma; however, many pts subsequently progress a...

Keywords:

Melanoma
anti pd 1
Dabrafenib
Trametinib
Pathology
Cancer research
Medicine
Mutant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations